Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Elixir Medical Announces Schedule of Programs for TCT 2016

Elixir Medical Corporation
Posted on: 19 Oct 16

Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it will showcase the first live case demonstration by transmission in the USA of its breakthrough DESolve® NXT Novolimus Eluting Bioresorbable Coronary Scaffold System at the 28th annual Transcatheter Cardiovascular Technologies (TCT) Conference in Washington, DC on Sunday, October 30. The Elixir-sponsored symposium is also scheduled for Sunday, October 30th from 6-8 PM.

Elixir will announce new six-month data for its 120µm thin-strut DESolve Cx Fully Bioresorbable Novolimus Eluting Coronary Scaffold System and the four-year data on the DESolve Novolimus eluting scaffold during the scientific conference. Following are the details of Elixir Medical’s programs and activities at TCT in Eastern Standard Time (EST):

Saturday, October 29:

6:00 – 8:00 PM, Washington Convention Center Hall B, Lower Level
Challenging Case: An 80-year-old patient with multiple metal allergies and a bifurcation lesion treated with DESolve (included kissing balloon).
Practical Solution: Can Bioresorbable Scaffold (BRS) be the treatment for a different BRS Restenosis and Bioresorbable Scaffold Recoil?

Sunday, October 30:

10:30 AM, Washington Convention Center, Main Arena
LIVE CASE from Antwerp Cardiovascular Centre, ZNA, Antwerp, Belgium, by Stefan Verheye, MD, PhD
Fully Bioresorbable DESolve® NXT Novolimus Eluting Coronary Scaffold System

Sunday, October 30:

6 – 8 PM, Marriott Marquis Ballroom, Salon 6, Level M2
Elixir-sponsored Symposium:
DESolve® NXT – The Next Breakthrough in BRS Innovation

Chairs

  • Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
  • Martin B. Leon, MD, New York – Presbyterian Hospital / Columbia University Medical Center, New York, NY, USA
  • Roxana Mehran, MD, Mount Sinai Hospital, New York, NY, USA

Panelist Faculty

  • Niels R. Holm, MD, Aarhus University Hospital, Aarhus N, Denmark
  • Holger Nef, MD, PhD Head of the Cardiac Catheterization Laboratory, University Hospital Giessen, Giessen, Germany
  • Jack Wei Chieh Tan, MD, National Heart Centre Singapore, Singapore

Agenda

  • Session Objectives
  • DESolve Evolution – DESolve, Cx, NXT, NXT Plus
  • DESolve Nx 4-year follow-up
  • DESolve Cx 6-month follow-up
  • DESolve Real World: Europe experience
  • DESolve Real World: Asia experience
  • BIFSORB
  • Indication-specific BRS Therapies – AMITY, PRAVA
  • Session Key Learning

Space is limited: Please register in advance at http://www.crf.org/tct/agenda/satellite-programs

Monday, October 31:

Device Specifications and Clinical Program Update

10:34 AM,Washington Convention Center, Room 305, Level 3
DESyne BD: TCT 32: Prospective, Multi-Center Evaluation of the DESyne BD Novolimus-Eluting Coronary Stent: 4-year clinical results.
Ricardo Costa, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

12:45 PM, Washington Convention Center, Room 103B, Level 1
DESolve: TCT 32: Prospective, Multi-Center Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and Four-Year Clinical and Imaging Results
Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

4:22 PM, Washington Convention Center Room 151, Level 1
DESolve NXT, Cx and AMITY: Unique properties and results from 150 µm To 120 µm.
Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

Tuesday, November 1:

10:14 AM, Washington Convention Center Room 103B, Level 1
CASE #9: Value of self-expanding properties using DESolve BRS in a bifurcation
Niels R. Holm, MD, Aarhus University Hospital, Aarhus N, Denmark

2:00 PM,Washington Convention Center Room 207, Level 2
Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
DESolve: Impact of Different PLLA Polymers and BRS Construction on Implant Technique: From Absorb to DESolve to Fantom to Manli and More

7:22 PM, Marriott Marquis, Salon 1-4, Level M2
Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
DESolve: Thin Struts With Self-Correcting Property (DESolve)

Elixir Medical will have a booth at TCT: Booth 1309, Exhibit Hall. The booth will be open Sunday, October 30 and Monday, October 31 from 9 am to 5 pm, and Tuesday, November 1 from 9 am to 2 pm.

About Elixir Medical

Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161019005484/en/

Business Wire
www.businesswire.com

Last updated on: 19/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.